Spots Global Cancer Trial Database for Abiraterone-Rechallenge Study for CRPC Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Abiraterone-Rechallenge Study for CRPC Patients
Official Title: An Open Label Biomarker Driven Phase II Clinical Trial of Abiraterone Acetate (AA) Re-Challenge in Patients With Metastatic Castration-Resistant Prostate Cancer and Prior Response to AA
Study ID: NCT02656615
Conditions
Interventions
Study Description
Brief Summary: To assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone.
Detailed Description: To assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone. CRPC patients with prior response to abiraterone (confirmed PSA Response) and progression can be re-challenged with abiraterone. Patients may have received treatment with docetaxel, enzalutamide and radium-223.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Cantonal Hospital Chur, Chur, Graubuenden, Switzerland
University Hospital Basel, Basel, , Switzerland
Cantonal Hospital St.Gallen, St.Gallen, , Switzerland
Contact Details
Name: Aurelius G Omlin, MD
Affiliation: Cantonal Hospital St. Gallen
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
